Milestone Pharmaceuticals Inc.

NasdaqGS:MIST 주식 보고서

시가총액: US$121.9m

Milestone Pharmaceuticals 미래 성장

Future 기준 확인 5/6

Milestone Pharmaceuticals은 연간 수입과 매출이 각각 63.6%와 70.6% 증가할 것으로 예상되고 EPS는 연간 63.9%만큼 증가할 것으로 예상됩니다.

주요 정보

63.6%

수익 성장률

63.9%

EPS 성장률

Pharmaceuticals 수익 성장23.9%
매출 성장률70.6%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트14 Nov 2024

최근 미래 성장 업데이트

Recent updates

Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Nov 06
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

Sep 13
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Mar 07
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Oct 15
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02
Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15
What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

수익 및 매출 성장 예측

NasdaqGS:MIST - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202656-11-30-142
12/31/20256-64-49-384
12/31/2024N/A-40-29-284
9/30/2024N/A-43-32-32N/A
6/30/2024N/A-48-37-37N/A
3/31/2024N/A-55-42-41N/A
12/31/20231-60-47-46N/A
9/30/20235-59-50-49N/A
6/30/20236-59-49-49N/A
3/31/20236-59-53-52N/A
12/31/20225-58-53-52N/A
9/30/20222-62-52-52N/A
6/30/2022N/A-62-50-50N/A
3/31/202215-44-35-35N/A
12/31/202115-43-33-33N/A
9/30/202115-35-30-30N/A
6/30/202115-32-28-28N/A
3/31/2021N/A-46-45-45N/A
12/31/2020N/A-50-51-51N/A
9/30/2020N/A-60-59-59N/A
6/30/2020N/A-60-60-60N/A
3/31/2020N/A-61-55-54N/A
12/31/2019N/A-55-52-51N/A
9/30/2019N/A-47-42-42N/A
6/30/2019N/A-40-39-39N/A
3/31/2019N/A-29-31-31N/A
12/31/2018N/A-23-21-21N/A

애널리스트 미래 성장 예측

수입 대 저축률: MIST 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: MIST (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: MIST 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: MIST 의 수익(연간 70.6% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: MIST 의 수익(연간 70.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: MIST 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견